Antiproliferative Peptide Coibamide A

Summary

 

Technology Description

 

Researchers at Oregon State University have discovered, isolated, and purified a new antiproliferative compound, Coibamide A, which provides for a new and potent family of antiproliferative compounds. The peptidic molecular structure of Coibamide A presents a large number of possible combinations and permutations of component amino acid residues for structure activity relationship studies and/or drug development. Oregon State University is seeking a commercial licensee and research collaborator to further develop and bring this technology to market. If you are interested in learning more about this opportunity, please contact the licensing manager.

 

Features & Benefits

 

  • Strong antiproliferative activity, especially against aggressive tumor types such as melanoma and CNS tumors.

 

Applications

 

  • Antitumor

 

Background of Invention

 

Cancer is one of the leading causes of morbidity and mortality worldwide, and the number of cases is expected to rise to 22 million over the next 2 decades. Modified natural products continue to be an important source for new drugs that address unmet needs in the battle against cancer.

 

Status

 

Issued U.S. Patent No. 8.034,780

 

 

 

Patent Information:
Tech ID:
OSU-06-52
Category(s):
Therapeutics
Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Kerry McPhail
Rebecca Medina
William Gerwick
Douglas Goeger
Susan Moobery
Todd Capson
Keywords:
Biomedical
Biotechnology
Medical Science & Technologies
Pharmaceuticals
© 2017. All Rights Reserved. Powered by Inteum